We are live on ! Find out more
PRDS

Pardes Biosciences, Inc. Common Stock
PRDS

Delisted

PRDS was delisted on the 30th of August, 2023.

Back to rankings

61 hedge funds and large institutions have $175M invested in Pardes Biosciences, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 15 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

1% more capital invested

Capital invested by funds: $174M → $175M (+$1.11M)

12% less funds holding

Funds holding: 69 → 61 (-8)

62% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 13

73% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 15

75% less funds holding in top 10

Funds holding in top 10: 4 → 1 (-3)

Holders
61
Holders Change
-8
Holders Change %
-11.59%
% of All Funds
1.07%
Holding in Top 10
1
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-75%
% of All Funds
0.02%
New
5
Increased
4
Reduced
15
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PIM
Platinum Investment Management
Australia
+$9.6M
2
ACA
Arena Capital Advisors
California
+$5.29M
3
EC
EcoR1 Capital
California
+$2.2M
4
OPU
Omni Partners US
California
+$2M
5
WP
Woodline Partners
California
+$309K

Top Sellers

Rank Fund Capital Flow
1
MAMNY
Marathon Asset Management (New York)
New York
-$5.79M
2
GCL
Glazer Capital LLC
New York
-$1.92M
3
Citadel Advisors
Citadel Advisors
Florida
-$1.66M
4
SRCM
Sage Rock Capital Management
New York
-$1.59M
5
C
Chescapmanager
Maryland
-$1.38M
Name Holding Trade Value Shares
Change 		Change in
Stake
MI
51
MMCAP International
Cayman Islands
$164K – – –
BFM
52
Boothbay Fund Management
New York
$149K – – –
Toronto Dominion Bank
53
Toronto Dominion Bank
Ontario, Canada
$119K – – –
Calamos Advisors
54
Calamos Advisors
Illinois
$100K – – –
DCM
55
Dupont Capital Management
Delaware
$100K – – –
HM
56
Harvest Management
New York
$100K – – –
VI
57
Vestcor Inc
New Brunswick, Canada
$4K – – –
UBS Group
58
UBS Group
Switzerland
$2K -$14.6K -1,465 -89%
Royal Bank of Canada
59
Royal Bank of Canada
Ontario, Canada
$1K +$785 +79 New
Morgan Stanley
60
Morgan Stanley
New York
$1K +$983 +99 New
Walleye Capital
61
Walleye Capital
New York
$177 -$6.57K -661 -4%
MAMNY
62
Marathon Asset Management (New York)
New York
– -$5.79M -580,000 Closed
SCM
63
Shaolin Capital Management
Florida
– -$1.25M -125,000 Closed
LGM
64
Logos Global Management
California
– -$1.23M -123,543 Closed
GL
65
Governors Lane
New York
– -$998K -100,000 Closed
MAM
66
Melqart Asset Management
United Kingdom
– -$649K -65,000 Closed
RCM
67
Radcliffe Capital Management
Pennsylvania
– -$499K -50,000 Closed
PC
68
Periscope Capital
Ontario, Canada
– -$458K -45,873 Closed
HP
69
Hound Partners
New York
– -$348K -34,907 Closed
EAM
70
Exos Asset Management
New York
– -$200K -20,000 Closed
SCC
71
Spring Creek Capital
Kansas
– -$200K -20,000 Closed
TCM
72
Tenor Capital Management
New York
– -$100K -10,000 Closed
WAM
73
Wolverine Asset Management
Illinois
– -$82K -8,228 Closed
TRCT
74
Tower Research Capital (TRC)
New York
– -$1K -100 Closed
1 2
3

PRDS Hedge Fund Activity: Q3 2021 in Review

61 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Pardes Biosciences, Inc. Common Stock (PRDS) for Q3 2021, worth a combined $175M — up 0.64% from $174M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of PRDS and 5 opened new positions — a net loss of 8 holders — while 15 trimmed existing stakes and 4 added.

The largest buyer was Platinum Investment Management, opening a new position worth an estimated $9.6M. The largest seller was Marathon Asset Management (New York), exiting entirely with an estimated $5.79M sold.

  • 61 institutional investors held Pardes Biosciences, Inc. Common Stock (PRDS) as of Q3 2021, down from 69 in Q2 2021.
  • Funds reported $175M of Pardes Biosciences, Inc. Common Stock stock for Q3 2021, up 0.64% quarter-over-quarter.
  • 5 funds opened new Pardes Biosciences, Inc. Common Stock positions in Q3 2021 and 13 closed out, a net change of -8 holders.
  • The largest Pardes Biosciences, Inc. Common Stock buyer in Q3 2021 was Platinum Investment Management, an estimated $9.6M added.
  • The largest Pardes Biosciences, Inc. Common Stock seller in Q3 2021 was Marathon Asset Management (New York), an estimated $5.79M sold.

Based on aggregated 13F filings for Q3 2021.